SG Americas Securities’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-519
Closed -$8K 3120
2024
Q1
$8K Sell
519
-2,085
-80% -$45K ﹤0.01% 2896
2023
Q4
$73K Buy
+2,604
New +$68.4K ﹤0.01% 2848
2023
Q2
Sell
-2,184
Closed -$248K 2808
2023
Q1
$248K Buy
2,184
+1,472
+207% +$159K ﹤0.01% 2263
2022
Q4
$80K Sell
712
-84
-11% -$11.3K ﹤0.01% 2777
2022
Q3
$102K Buy
+796
New +$81.5K ﹤0.01% 2851
2022
Q1
Sell
-601
Closed -$100K 3254
2021
Q4
$100K Sell
601
-25,896
-98% -$4.11M ﹤0.01% 3087
2021
Q3
$3.69M Buy
26,497
+25,734
+3,373% +$5.04M 0.02% 749
2021
Q2
$364K Sell
763
-80
-9% -$33.8K ﹤0.01% 2085
2021
Q1
$347K Sell
843
-101
-11% -$46.5K ﹤0.01% 2266
2020
Q4
$463K Buy
+944
New +$553K ﹤0.01% 2033
2020
Q3
Sell
-1,409
Closed -$134K 3141
2020
Q2
$134K Buy
+1,409
New +$124K ﹤0.01% 3170
2019
Q3
Sell
-526
Closed -$34K 3133
2019
Q2
$34K Buy
+526
New +$49.9K ﹤0.01% 2957

Other funds holding MCRB

SG Americas Securities's MCRB Position: Q2 2024 in Review

SG Americas Securities sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 519 shares — an estimated $8K sold.

SG Americas Securities first reported a position in MCRB in Q2 2019 and held it in 12 quarters. The position peaked at $3.69M in Q3 2021. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • SG Americas Securities reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 519 Seres Therapeutics shares in Q2 2024, an estimated $8K.
  • SG Americas Securities first reported a position in Seres Therapeutics in Q2 2019 and held it in 12 quarters.
  • SG Americas Securities's Seres Therapeutics position peaked at $3.69M in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.